Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C brings in $33mm for Zafgen

Executive Summary

Zafgen Inc. (obesity therapeutics) has raised $33mm through its Series C venture round. Atlas Venture and Third Rock Ventures led the financing and were joined by other current shareholders. The company will use the money to move ZGN433, its lead methionine aminopeptidase 2 inhibitor, into Phase II studies within the next year. The drug candidate is an alternative to bariatric surgery for severely obese patients.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies